Clinical trials: Dialysis Amyloidosis
Hemodialysis-Associated Amyloidosis, Dialysis Amyloidosis
A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis
This is an open label, cross-over group, single-centre randomised controlled trial comparing Medium Cut Off Dialyser with High Flux Dialyser in patients with end-stage renal disease on chronic haemodialysis.
- Conditions
- Hemodialysis-Associated Amyloidosis, Dialysis Amyloidosis, Quality of Life
- Trial name
- HD-1 (NCT04160351)
- Testing
- Theranova 400, Elisio-19H
- Where
- Malaysia
- Volunteers
- 44 people
- Sponsor
- Selayang Hospital
Dialysis Amyloidosis, Hypotension
Studying the Effect of Dialysate Temperature on Toxin Removal and Hypotension
Hemodialysis (HD) is widely used treatment for end stage renal diseases (ESRD) patients. The chief aims of HD are solute and fluid removal.
- Trial name
- NCT02064153
- Testing
- Cool dialysate, Warm dialysate
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- National University Hospital, Singapore
End Stage Renal Disease, Dialysis Related Complication
Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer
The aim of this study is to evaluate the removal of midle molecules and inflammatory cytokines with the Theranova-500 ™ dialyzer (medium cut-off membrane, Baxter®) versus a high flux dialyzer Elisio-21H ™ (High-flux membrane…
- Conditions
- End Stage Renal Disease, Dialysis Related Complication, Dialysis Amyloidosis
- Trial name
- THERANOVA (NCT03211676)
- Testing
- Theranova-500 dialyzer, Elisio-21H
- Where
- France
- Volunteers
- 49 people
- Sponsor
- Poitiers University Hospital
Dialysis Amyloidosis
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Dialysis-related amyloidosis (DRA) is a serious complication of long-term hemodialysis (HD). Its pathogenic mechanism involves accumulation of β2-microglobulin (β2M) in the blood.
- Trial name
- NCT02952144
- Testing
- Lixelle® treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kaneka Medical America LLC